Bar upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry

Cytometry

Volumn 27, Issue 3, 1997, Pages 275-282

  Boersma, Antonius W M ^a   Nooter, Kees ^a,b   Burger, Herman ^a   Kortland, Christine J ^a   Stoter, Gerrit ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Bax; Bax upregulation in early apoptotic cells; Bcl 2; Chemosensitivity; Flow cytometry; Germ cell tumor cell line NT2

Indexed keywords

PROTEIN BAX; BAX PROTEIN, HUMAN; CISPLATIN; ONCOPROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TESTIS TUMOR; TUMOR CELL LINE; BIOSYNTHESIS; CELL ADHESION; CELL CULTURE; CELL SEPARATION; DRUG EFFECT; METABOLISM; PATHOLOGY; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL ADHESION; CELL SEPARATION; CISPLATIN; FLOW CYTOMETRY; GERMINOMA; HUMANS; MALE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0030614676     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q     Document Type: Article

References (35)

1. Andree HAM, Reutelingsperger CPM, Hauptmann R, Hemker HC, Hermens WT, Willems GM: Binding of vascular anticoagulant α (VACα) to planar phospholipid bilayers. J Biol Chem 265:4923-4928, 1990.
2. Boersma AWM, Nooter K, Oostrum RG, Stoter G: Quantification of apoptotic cells with FITC-labeled annexin V in CHO cell cultures treated with cis-Pt. Cytometry 24:123-130, 1996.
3. Bosl GJ: Chemotherapy of germ cell tumors: Current status and future directions. Eur Urol 23:53-56, 1993.
4. Chresta CM, Masters JRW, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56:1834-1841, 1996.
5. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.
6. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skilleter DN: Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 286:331-334, 1992.
7. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808, 1992.
8. Demarcq C, Bunch RT, Creswell D, Eastman A: The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5:983-993, 1994.
9. DeVita VT, Hellman S, Rosenberg SA: Cancer, Principles and Practice of Oncology. Lippincott Company, Philadelphia, 1989, pp 3-2489.
10. Dive C, Hickman JA: Drug-target interactions: Only the first step in the commitment to a programmed cell death? Br J Cancer 64:192-196, 1991.
11. Eastman A, Barry MA: The origins of DNA breaks: A consequence of DNA damage, DNA repair, or apoptosis? Cancer Invest 10:229-240, 1992.
12. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207-2216, 1992.
13. 2+ and lipid-binding proteins. FEBS Lett 203:99-103, 1986.
14. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53:1945-1951, 1993.
15. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AM, Shellard SA: Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumors from untreated patients. Eur J Cancer Clin Oncol 30:832-837, 1994.
16. Kelland LR: The molecular basis of cisplatin sensitivity/resistance. Eur J Cancer Clin Oncol 30:725-727, 1994.
17. Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer chemotherapy. Cancer 73:2013-2026, 1994.
18. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
19. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, vanSchie RCAA, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545-1556, 1995.
20. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131-3135, 1994.
21. Miyashita T, Krajewski S, Krajewskia M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994.
22. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
23. Nooter K, Boersma AWM, Oostrum RG, Burger H, Jochemsen AG, Stoter G: Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdo-myosarcoma cell line. Br J Cancer 71:556-561, 1995.
24. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
25. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance therapy. J Cell Biochem 60:23-32, 1996.
26. Sark MWJ, Timmer-Bosscha H, Meijer C, Uges DRA, Sluiter WJ, Peters WHM, Mulder NH, de Vries EGE: Cellular basis for differential sensitivity to cisplatin in human germ cell tumor and colon carcinoma cell lines. B J Cancer 71:684-690, 1995.
27. Sato T, Kanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG, Reed JC: Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91:9238-9242, 1994.
28. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92:7834-7838, 1995.
29. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D: Immediate early up-regulation of Bax expression by p53 but not TGFβ1: A paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798, 1994.
30. Sen S, D'Incalci M: Apoptosis: Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307:122-127, 1992.
31. Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. JNCI 82:749-755, 1990.
32. Studzinski GP: Cell Growth and Apoptosis. A Practical Approach. IRL Press, Oxford, 1995, pp 1-166.
33. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306, 1980.
34. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death. Cell 80:285-291, 1995.
35. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743-3751, 1994.